Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment: ClinicalPosted by saikrishna on May 28th, 2018 Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 Acute Respiratory Distress Syndrome Disease Pipeline Drugs AssessmentOverview: Acute Respiratory Distress Syndrome is an acute lung dysfunction, which occurs as a result of injury or illness. It is known as adult respiratory distress syndrome, it may also affect children. In this condition small air sacs (alveoli) in lungs are accumulated with fluid which makes difficulty in passing of oxygen into blood stream. Symptoms of acute respiratory distress syndrome includes difficulty in breathing, rapid breathing, hyper ventilation. ARDS can be developed into deep infection which causes pneumonia, trauma. ARDS can be diagnosed by blood tests, chest x-rays and others. Treatment for the ARDS are mechanical ventilation, supplemental oxygen, fluid management and a technique called positive end expiratory pressure (PEEP) to help push the fluid out of air sacs, extracorporeal membrane oxygenation, human mesenchymal stem cells. A sample of this report is available upon request @ Segmentation: By Drugs, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:
By Route of Administration, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:
By Trial Phase, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:
By Company, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:
Space Analysis:
Like it? Share it! More by this author |